Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
- Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
- When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
- What to Do about the Feeling of Torschlusspanik?
October 27, 2017
- Women! Rock the Boat and Get Promoted
September 22, 2017
- Getting the Right Message
August 25, 2017
- Putting on Your Pants
July 21, 2017
- Reputable Combination
July 11, 2017
- What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
- Doubling Down on Digital
May 26, 2017
- Global Opportunities for Global Minds
April 21, 2017
- Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
- Some Japanese Pharmaceutical Workers May Slowly Be Working Themselves to Death
March 17, 2017
- The Best Recruiters Are Just a Little Paranoid
February 17, 2017
- 5 Killer Questions for HR to Ask Recruiters
January 20, 2017
- What Pharma Can Learn from the Airline Industry
December 16, 2016
- Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
- Reasons for a “Hold”
August 9, 2016
- It’s Time for Market Access to Play a Leading Role
April 22, 2016
- Biosimilars Are the New Black
March 25, 2016
ページ
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…